United Therapeutics Announces FDA Approval of Tyvaso DPI™
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/3/2026
- Wall St ends higher as stocks reclaim some shine
- Broadcom raises AI chip forecast as Big Tech keeps writing bigger checks
- Snowflake soars 20% on earnings beat and raised guidance
- Oil settles 1% higher, as US-Iran strikes threaten supplies
- Could Apple’s foldable iPhone be a $14B opportunity? Morgan Stanley weighs in
United Therapeutics Corp. (UTHR) PT Raised to $245 at Jefferies
May 24, 2022 9:00 AM EDTJefferies analyst Eun Yang raised the price target on United Therapeutics Corp. (NASDAQ: UTHR) to $245.00 (from $223.00) while maintaining a Buy rating.
The analyst commented, "Though FDA approval of Tyvaso DPI was cautiously anticipated, broad & clean approval for both indications without boxed warning for... More
